Longboard Pharmaceuticals, Inc.
Industry Group: Commercial Services
Country/Region: United States of America
Identifier: NAS:LBPH
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Commercial Services 261 out of 429
Universe
Global Universe 5247 out of 15080
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Longboard Pharmaceuticals, Inc. |
21.4
Medium
|
261 out of 429 |
Park24 Co., Ltd. |
22.2
Medium
|
283 out of 429 |
BlueFocus Intelligent Communications Group Co. Ltd. |
25.7
Medium
|
376 out of 429 |
China Wafer Level CSP Co., Ltd. |
26
Medium
|
378 out of 429 |
Eternal Asia Supply Chain Management Ltd. |
29.9
Medium
|
422 out of 429 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Longboard Pharmaceuticals, Inc.'s Exposure is Low
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Longboard Pharmaceuticals, Inc.'s Management of ESG Material Risk is Average